|
68 Companies |
|
79 Products |
|
79 Products |
|
71 Mechanisms of Action |
|
0 Trials |
|
484 News |
|
| «12345678910» |
- cyclosporin A microemulsion / Generic mfg.
Trial completion date: Evaluate Reversal of Pathological Epidermal Phenotype in Severe Atopic Dermatitis (AD) With Suppression of Immune Activation During Cyclosporine A Therapy (clinicaltrials.gov) - May 5, 2014
P=N/A, N=9, Active, not recruiting, Sponsor: Rockefeller University
Trial completion date: Mar 2013 --> Dec 2014
- cyclosporin A microemulsion / Generic mfg.
Enrollment closed: Evaluate Reversal of Pathological Epidermal Phenotype in Severe Atopic Dermatitis (AD) With Suppression of Immune Activation During Cyclosporine A Therapy (clinicaltrials.gov) - May 5, 2014
P=N/A, N=9, Active, not recruiting, Sponsor: Rockefeller University
Trial completion date: Mar 2013 --> Dec 2014 Completed --> Active, not recruiting
- Enrollment open, IO biomarker: VIDATOPIC: Impact of Vitamin D Supplementation on Severity of Pediatric Atopic Dermatitis (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=100, Recruiting, Sponsor: Pontificia Universidad Catolica de Chile
Completed --> Active, not recruiting Not yet recruiting --> Recruiting
- Enrollment open, IO biomarker: ADRN Barrier/Immunoprofiling Exploratory Pilot Study (clinicaltrials.gov) - Apr 24, 2014
P=N/A, N=180, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- tacrolimus topical / Generic mfg.
Adherence: Protopic Adherence and Efficacy in Korean Eczema Patient (clinicaltrials.gov) - Apr 23, 2014
P=N/A, N=50, Not yet recruiting, Sponsor: Pusan National University Hospital
- |||||||||| Eucrisa (crisaborole) / Pfizer
New P3 trial: CORE 2: Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis (clinicaltrials.gov) - Apr 17, 2014
P3, N=750, Recruiting, Sponsor: Anacor Pharmaceuticals, Inc.
- |||||||||| Eucrisa (crisaborole) / Pfizer
New P3 trial: CORE 1: Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis (clinicaltrials.gov) - Apr 17, 2014
P3, N=750, Recruiting, Sponsor: Anacor Pharmaceuticals, Inc.
- IO biomarker: ADRN Barrier/Immunoprofiling Exploratory Pilot Study (clinicaltrials.gov) - Apr 14, 2014
P=N/A, N=180, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- |||||||||| New P3 trial: PIPA: Prebiotics in Prevention of Atopy (clinicaltrials.gov) - Apr 14, 2014
P3, N=380, Completed, Sponsor: Federico II University
- ||||||| bepotastine immediate release / Generic mfg.
Trial completion: A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis (clinicaltrials.gov) - Apr 13, 2014
P3, N=303, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Enrollment change, IO biomarker: Interferon Responses in Eczema Herpeticum (clinicaltrials.gov) - Apr 13, 2014
P=N/A, N=120, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed N=75 --> 120
- pimecrolimus topical / Generic mfg.
Enrollment open: A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Apr 9, 2014
P1, N=30, Recruiting, Sponsor: LEO Pharma
N=75 --> 120 Not yet recruiting --> Recruiting
- Clinical: Assessment of Efficacy of the Consumption of a Heat-treated Lactobacillus Paracasei (GM080) on Atopic Dermatitis (clinicaltrials.gov) - Apr 2, 2014
P=N/A, N=126, Not yet recruiting, Sponsor: Nestlé
- | pimecrolimus topical / Generic mfg.
New P1 trial: A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Apr 2, 2014
P1, N=30, Recruiting, Sponsor: LEO Pharma
- Biomarker, Trial termination: ADVN Biomarker Registry Study (clinicaltrials.gov) - Mar 31, 2014
P=N/A, N=1099, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; This study was combined into DAIT ADRN-02
- ||| Enrollment open: COPES: Correlation Study Between PEST and SCORAD in Management of Atopic Dermatitis With Ceradan® Regimen (clinicaltrials.gov) - Mar 23, 2014
P=N/A, N=58, Recruiting, Sponsor: Hyphens Pharma Pte Ltd
Active, not recruiting --> Terminated; This study was combined into DAIT ADRN-02 Not yet recruiting --> Recruiting
- | Trial completion: Blue Light for Treating Eczema (clinicaltrials.gov) - Mar 20, 2014
P=N/A, N=21, Completed, Sponsor: Light and Health Venture
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Clinical: Placebo Effect in the Treatment of Atopic Dermatitis (clinicaltrials.gov) - Mar 19, 2014
P=N/A, N=140, Recruiting, Sponsor: Margitta Worm
- ||||| New P1/2 trial: A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis (clinicaltrials.gov) - Mar 19, 2014
P1/2, N=60, Recruiting, Sponsor: Eisai Co., Ltd.
- | SB011 / Sterna Biologicals
New P2a trial: Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of the Topical Formulation SB011 Applied to Lesional Skin in Patients With Atopic Eczema (clinicaltrials.gov) - Mar 4, 2014
P2a, N=26, Recruiting, Sponsor: Sterna Biologicals GmbH & Co. KG
- Photofrin (porfimer sodium) / Advanz Pharma
Trial withdrawal: Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light (clinicaltrials.gov) - Feb 27, 2014
P2, N=0, Withdrawn, Sponsor: Pinnacle Biologics Inc.
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Photofrin (porfimer sodium) / Advanz Pharma
Enrollment change: Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light (clinicaltrials.gov) - Feb 27, 2014
P2, N=0, Withdrawn, Sponsor: Pinnacle Biologics Inc.
Not yet recruiting --> Withdrawn N=20 --> 0
- |||| cobamamide liposomal (HL009) / Daewoong Pharma
Trial completion: Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Feb 23, 2014
P2, N=120, Completed, Sponsor: HanAll BioPharma Co., Ltd.
N=20 --> 0 Recruiting --> Completed
- |||| pimecrolimus topical / Generic mfg.
Trial completion: Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis (clinicaltrials.gov) - Feb 22, 2014
P4, N=200, Completed, Sponsor: Novartis
Recruiting --> Completed No longer recruiting --> Completed
- |||| Trial completion: Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=75, Completed, Sponsor: Anesiva, Inc.
No longer recruiting --> Completed Recruiting --> Completed
- |||| pimecrolimus topical / Generic mfg.
Trial completion: Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis (clinicaltrials.gov) - Feb 22, 2014
P4, N=400, Completed, Sponsor: Novartis
Recruiting --> Completed No longer recruiting --> Completed
- |||| pimecrolimus topical / Generic mfg.
Trial completion: Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients (clinicaltrials.gov) - Feb 22, 2014
P4, N=200, Completed, Sponsor: Novartis
No longer recruiting --> Completed No longer recruiting --> Completed
- |||| pimecrolimus topical / Generic mfg., fluticasone propionate / Generic mfg.
Trial completion, Combination therapy: Combination Therapy for Atopic Dermatitis (clinicaltrials.gov) - Feb 22, 2014
P4, N=90, Completed, Sponsor: Children's Hospital of Philadelphia
No longer recruiting --> Completed No longer recruiting --> Completed
- |||| pimecrolimus topical / Generic mfg.
Trial completion: Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis (clinicaltrials.gov) - Feb 22, 2014
P4, N=70, Completed, Sponsor: Novartis
No longer recruiting --> Completed No longer recruiting --> Completed
- |||| pimecrolimus topical / Generic mfg.
Trial completion, HEOR: Quality of Life Study in Adults With Facial Eczema (clinicaltrials.gov) - Feb 22, 2014
P4, N=76, Completed, Sponsor: Novartis
No longer recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=40, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed Recruiting --> Completed
- Trial termination: Narrow-band (NB)-UVB vs. Bath-PUVA and NB-UVB Plus Salt Water Baths in Atopic Dermatitis (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=10, Terminated, Sponsor: Ruhr University of Bochum
Recruiting --> Completed Recruiting --> Terminated; Difficulties with the Recruitement
- Enrollment change: Narrow-band (NB)-UVB vs. Bath-PUVA and NB-UVB Plus Salt Water Baths in Atopic Dermatitis (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=10, Terminated, Sponsor: Ruhr University of Bochum
Recruiting --> Terminated; Difficulties with the Recruitement N=50 --> 10
- Clinical: A Psychoeducational Prevention for the Treatment of Atopic Dermatitis in Youth and Their Families (clinicaltrials.gov) - Feb 18, 2014
P=N/A, N=50, Not yet recruiting, Sponsor: Seton Family of Hospitals
- ||||||| Trial completion: Emollients in the Management of Atopic Dermatitis (clinicaltrials.gov) - Feb 17, 2014
P3, N=347, Completed, Sponsor: Pierre Fabre Medicament
N=50 --> 10 Active, not recruiting --> Completed
- cyclosporin A microemulsion / Generic mfg.
Enrollment change: Evaluate Reversal of Pathological Epidermal Phenotype in Severe Atopic Dermatitis (AD) With Suppression of Immune Activation During Cyclosporine A Therapy (clinicaltrials.gov) - Feb 10, 2014
P=N/A, N=9, Completed, Sponsor: Rockefeller University
Active, not recruiting --> Completed N=20 --> 9
- cyclosporin A microemulsion / Generic mfg.
Trial completion: Evaluate Reversal of Pathological Epidermal Phenotype in Severe Atopic Dermatitis (AD) With Suppression of Immune Activation During Cyclosporine A Therapy (clinicaltrials.gov) - Feb 10, 2014
P=N/A, N=9, Completed, Sponsor: Rockefeller University
N=20 --> 9 Recruiting --> Completed
- Trial completion: Effect of Oral Vitamin D Supplement on Atopic Dermatitis; A Clinical Trial With Staphylococcus Aureus Colonization Determination (clinicaltrials.gov) - Feb 5, 2014
P=N/A, N=20, Completed, Sponsor: Srinakharinwirot University
Recruiting --> Completed Not yet recruiting --> Completed
- |||| Enrollment open: A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis (clinicaltrials.gov) - Feb 5, 2014
P4, N=120, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Stelara (ustekinumab) / J&J
Enrollment open: A Study of Ustekinumab (STELARA (clinicaltrials.gov) - Jan 27, 2014
P2, N=72, Recruiting, Sponsor: Janssen Pharmaceutical K.K.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Dupixent (dupilumab) / Sanofi, Regeneron
Biomarker, Enrollment change: Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Jan 22, 2014
P2, N=380, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting N=240 --> 380
- ||| Dupixent (dupilumab) / Sanofi, Regeneron
Biomarker, Enrollment closed: Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Jan 22, 2014
P2, N=380, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
N=240 --> 380 Recruiting --> Active, not recruiting
- |||| lotamilast 0.5% ointment (DMVT-501 0.5% ointment) / Roivant
Trial completion: A Phase 2 Study of E6005 in Patients With Atopic Dermatitis (clinicaltrials.gov) - Jan 20, 2014
P2, N=78, Completed, Sponsor: Eisai Co., Ltd.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial withdrawal: Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD) (clinicaltrials.gov) - Jan 16, 2014
P1, N=0, Withdrawn, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Completed Terminated --> Withdrawn
- ||| difamilast (MM36) / Otsuka, Medimetriks
Trial completion: A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis (clinicaltrials.gov) - Jan 15, 2014
P1, N=92, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Terminated --> Withdrawn Recruiting --> Completed
- |||| Trial completion: An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Jan 13, 2014
P2, N=151, Completed, Sponsor: PreCision Dermatology, Inc.
Recruiting --> Completed Recruiting --> Completed
- MRX 6 / Akari Therap
New P1/2 trial: Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2% (clinicaltrials.gov) - Jan 7, 2014
P1/2, N=0, Not yet recruiting, Sponsor: Celsus Therapeutics PLC
- Preclinical: The Effect of Bathing and Moisturizers on Skin Hydration in Atopic Dermatitis: an in Vivo Study (clinicaltrials.gov) - Jan 5, 2014
P=N/A, N=22, Completed, Sponsor: Srinakharinwirot University
- |||| Xeljanz (tofacitinib) / Pfizer
Clinical: Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema) (clinicaltrials.gov) - Dec 28, 2013
P2, N=70, Recruiting, Sponsor: Pfizer
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| MEDI 4212 / AstraZeneca
Trial completion: A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL (clinicaltrials.gov) - Dec 15, 2013
P1, N=86, Completed, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed